Igm Biosciences Inc (IGMS) Return on Assets ROA from the second quarter of 2025 to second quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Igm Biosciences Inc   (NASDAQ: IGMS)


Igm Biosciences Inc 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Igm Biosciences Inc 's ROA in the second quarter of 2025?
Igm Biosciences Inc recorded a cumulative net loss of $-53 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -26.42%.

However, within the Healthcare sector 396 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2025 quarter, so far to 3666, from total ROA ranking in the first quarter of 2025 at 4360.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Total Assets Change -64.69 % -39.69 % -41.33 % -39.24 % -31.62 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -53 -199 -196 -220 -220
Return On Assets (TTM) -26.42 % -79.21 % -68.67 % -67.58 % -59.84 %
IGMS's Total Ranking # 3666 # 4360 # 4934 # 4369 # 4352
Total Assets (TTM) in million 107 207 228 266 303
Seq. Total Assets Change -48.29 % -9.31 % -14.33 % -12.13 % -11.67 %
Seq. Net Income Change - - - - -

IGMS's 5 Years Annual ROA >> Back to IGMS Management Effectiveness >> Compare IGMS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 147
Sector # 397
Overall # 3618

Return On Assets Statistics
High Average Low
-2.73 %
-40.52 %
-71.43 %
(Sep 30 2019)   (Mar 31 2025)



  News about Igm Biosciences Inc Return on Assets ROA

IGM Biosciences Hits a Roadblock: Autoimmunity Pipeline Programs Halted Amid $220 Million Loss as Market Soars,

IGM Biosciences Halts Key Pipeline Programs Amid Financial Struggles and Market Optimism IntroductionIn a significant strategic shift, IGM Biosciences Inc. announced it will halt further development of its promising autoimmune pipeline programs, particularly imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3). This decision arises against a backdrop of substantial financial losses, raising questions about the company’s future amidst a vibrant healthcare market. Financial OverviewIGM Biosciences has reported a staggering cumulative net loss of $220 million for the twelve months ending in the third quarter of 2024. This financial downturn translates into a negative return on assets (ROA) of -67.58%. Furthermore, despite these challenges, the company s overall ROA ranking has shown a slight improvement, moving up from 3958 to 3846 in the Healthcare sector as of September 30, 2024. However, it s important to note that 648 other companies in the same sector have outperformed IGM in terms of ROA.



Financial Statements
Igm Biosciences Inc 's Assets $ 107 million IGMS's Balance sheet
Igm Biosciences Inc 's Income $ 98 million Quarterly IGMS's Income Statement
IGMS's Income by Division See IGMS's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020
Y / Y Total Assets Change -41.33 % -18.12 % 74.44 % -31.51 % 59.67 %
Total Assets in million 228 389 475 272 397
Y / Y Net Income Change - - - - -
Net Income in million -196 -246 -221 -165 -81
Annual Return On Assets -85.83 % -63.37 % -46.56 % -60.67 % -20.47 %

IGMS's 5 Years Annual ROA >> Back to IGMS Management Effectiveness >> Compare IGMS ROA to its Competitors



More Return On Assets Ratios
IGMS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IGMS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IGMS's Competitors
Subscribers only: Roa for Igm Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for IGMS's Customers

You may also want to know
IGMS's Roi IGMS's Inventory Turnover Ratio IGMS's Growth Rates IGMS's Dividend Comparisons
IGMS's Profitability Ratios IGMS's Asset Turnover Ratio IGMS's Dividend Growth
IGMS's Roe IGMS's Valuation Ratios IGMS's Financial Strength Ratios IGMS's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector ROA

Date modified: 2026-09-18T13:11:06+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.